Dr. Miguel Divo, a lung specialist at Brigham and Women’s Hospital, sits in an exam room, across from one of his patients with asthma. Joel Rubinstein, a retired psychiatrist, is about to get a ...

Most people with asthma and other lung diseases have no idea that commonly prescribed inhalers are helping make the planet warmer. Each puff has about the same climate impact as driving a gas-powered ...

During an asthma check-up at Brigham and Women's Hospital in Boston, Joel Rubinstein gets a surprising pitch — for the planet, as well as his health. His pulmonologist, Dr. Miguel Divo, explains that ...

This story is free to read because readers choose to support LAist. If you find value in independent local reporting, make a donation to power our newsroom today. Listen 3:54 Listen to the Story ...

The inhaler you rely on for breathing may contribute to the planet's warming. However, there's a potential large-scale solution on the horizon. As Boston's WBUR reports, the little boot-shaped ...

Miguel Divo shows his patient, Joel Rubinstein, a dry powder inhaler. It has a much lower carbon footprint than a traditional inhaler while being equally effective for many patients with asthma. Jesse ...

There was a notable gap in effectiveness between metered-dose and dry-powder formulations of single-inhaler triple therapy for chronic obstructive pulmonary disease (COPD), according to real-world ...

Please provide your email address to receive an email when new articles are posted on . “Many health care systems are discussing a transition to dry-powder inhalers that have a lower carbon footprint ...

Please provide your email address to receive an email when new articles are posted on . Almost all of the estimated 1.15 MMT of CO 2 equivalent emissions in 2022 came from metered-dose inhalers. The ...

The Food and Drug Administration (FDA) has approved Tyvaso DPI™ (treprostinil) inhalation powder for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) and pulmonary hypertension ...

Aptar Pharma pulled the trigger on a deal for Pharmaxis’ Orbital high payload dry powder inhaler technology, paying $2.5 million for a worldwide license with the same again to follow if it chooses to ...